NRAMP1 Polymorphisms like Susceptibility Marker in Mexican Focus of Cutaneous Leishmaniasis
Table 4
Genotype frequency of the NRAMP1 polymorphisms in patients requiring high doses of Glucantime (HDG).
Genotypes
CL-HDG (%)
CL (%)
value
OR (95% CI)
Exon 3 274 C/C
2 (12.5)
48 (41.73)
22.69
3.94 (0.83–18.59)
Exon 3 274 C/T
2 (12.5)
51 (44.34)
Exon 3 274 T/T
9 (69.23)
16 (13.91)
Exon 8 823 C/C
9 (69.23)
92 (80)
15.43
1.77 (0.50–6.28)
Exon 8 823 C/T
0
18 (15.65)
Exon 8 823 T/T
4 (30.76)
5 (4.34)
Exon 15 D543N G/G
10 (76.92)
75 (65.21)
31.75
0.56 (0.14–2.16)
Exon 15 D543N G/A
0
40 (34.78)
Exon 15 D543N A/A
3 (23.07)
0
3′UTR TGTG/TGTG
8 (61.53)
65 (56.52)
Not statistically significant
3′UTR TGTG/del
0
3 (2.6)
3′UTR del/del
5 (38.46)
47 (40.86)
value = Chi-square value with in the presence of the mutation and requirement of high doses of Glucantime. OR = odds ratio (95% confidence interval). UTR = untranslated region. del = deletion.
